Meister Supply 99% Medical Grade Atosiban Powder CAS 90779-69-4 Bulk Atosiban Powder

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: MEI----28450
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Test Method: HPLC
• Storage: Store Cool Dry Place
• Market: Worldwide
• Mf: C43h67n11o12s2
• MW: 994.189
• CAS: 90779-69-4
• Boiling Point: 1469.0±65.0 °c at 760 Mmhg
• Transport Package: Aluminium Foil Bag
• Specification: 99%
• Trademark: Meister
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

Meister Supply 99% Medical Grade Atosiban Powder CAS 90779-69-4

Product Description

 

Product Name	Atosiban/Atosiban Impurtiy
CAS NO.	90779-69-4
Appearance	White Powder
Purity	99%
Density	1.254±0.06 g/cm^3
Boiling Point	1469.0±65.0 °C
Acidity Coefficient (pKa)	12.81±0.70
Solubility	H2O: ≤100 mg/mL
Chemical Structure
Application	Drug peptides, Intermediates&Fine Chemicals
Usage	Competitive antagonist of the cyclic peptide oxytocin receptor in the uterus, decidua and fetal membranes.
Storage	Sealed containers at cool and dry place.Protect from sunlight, moisture and pest infestation.

Atosiban was introduced  as an injectable inhibitor of preterm labor, a major cause of infant morbidity and mortality. This peptidic oxytocin analog is an antagonist of the vasopressin V1a receptor and of the oxytocin receptor which is found in dramatically increased concentration in the uterine myometrium of pregnant women near term. It competitively inhibited contractions in the pregnant guinea pig uterus induced by oxytocin and vasopressin. In a multicenter, double-blind, placebo-controlled trial, treatment with atosiban caused pregnancy prolongation for up to 7 days in women with more than 28 weeks of gestation. In a comparative clinical trial, atosiban showed a comparable tocolytic action (uterine relaxant) to ritodrine but the former was significantly better tolerated, especially with regards to maternal cardiovascular side effects. In healthy volunteers, plasma levels of atosiban decreased bi-exponentially with an initial and a terminal half-life of 21 min and 1.7h respectively.

Function

Atosiban was introduced in the UK as an injectable inhibitor of preterm labor, a major cause of infant morbidity and mortality. This peptidic oxytocin analog is an antagonist of the vasopressin V1a receptor and of the oxytocin receptor which is found in dramatically increased concentration in the uterine myometrium of pregnant women near term. It competitively inhibited contractions in the pregnant guinea pig uterus induced by oxytocin and vasopressin. In a multicenter, double-blind, placebo-controlled trial, treatment with atosiban caused pregnancy prolongation for up to 7 days in women with more than 28 weeks of gestation. In a comparative clinical trial, atosiban showed a comparable tocolytic action (uterine relaxant) to ritodrine but the former was significantly better tolerated, especially with regards to maternal cardiovascular side effects. 

Application

Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphatefrom the myometrial cell membrane. 

Atosiban is useful in improving the pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET) in patients with repeated implantation failure (RIF). The pregnancy rate improved from zero to 43.7%.

Detailed Photos

Related product

Shipping&Payment